If you’ve been following the regulatory tug-of-war over peptide access in the United States, this week brought the most significant development yet. On 1 July 2026, FDA staff reviewers published their assessment ahead of a crucial advisory committee meeting scheduled for late July - and their conclusion was blunt: there isn’t enough evidence to support expanded access to the peptides that the research community has been asking for.
What’s Happening
The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee is set to meet later this month to review seven popular research peptides for possible inclusion on the agency’s 503A Bulks List. The peptides under review include BPC-157, TB-500, KPV, and MOTs-C - compounds that have massive followings in the research and wellness communities but currently sit in a regulatory grey zone.
Being added to the 503A Bulks List wouldn’t make these peptides FDA-approved. What it would do is create a legal pathway for compounding pharmacies to manufacture them under physician supervision, with proper purity testing and labelling oversight. For anyone currently sourcing these compounds through less regulated channels, that would be a meaningful step up in quality assurance.
The Political Angle
Here’s where it gets complicated. US Health Secretary Robert F. Kennedy Jr. has been publicly pushing to expand access to peptides, and in recent months he’s reshaped the advisory committee by adding members who are broadly sympathetic to that position. According to reporting from NBC News and Reuters, FDA career scientists are concerned that the panel composition doesn’t reflect the usual evidence-based selection process.
Healio reported that the advisory committee membership includes several experts who have previously promoted peptide use in their clinical practices, raising questions about conflicts of interest. The FDA staff review noted that for the seven peptides under consideration, the existing clinical evidence doesn’t meet the threshold the agency typically requires for compounding eligibility.
What the Research Says
This is where the nuance matters. The lack of FDA approval for peptides like BPC-157 doesn’t necessarily mean they don’t work - it means the type of large-scale, randomised controlled trials that the FDA requires haven’t been completed. Much of the existing evidence comes from animal studies, small human trials, and observational data.
BPC-157, for example, has a substantial body of preclinical research showing tissue-protective and healing properties. TB-500 (thymosin beta-4) has been studied for wound healing and tissue repair. But the gap between “promising preclinical data” and “sufficient evidence for regulatory approval” is significant, and the FDA staff review made clear that the current evidence falls on the wrong side of that gap.
The January 2026 analysis referenced in recent reporting found that roughly 3 in 10 research-grade peptide products fail basic quality checks - they’re mislabeled, below purity thresholds, or dosed incorrectly. That finding cuts both ways: it argues for better regulation, but it also highlights the risks of the current unregulated market.
The Hone Health Survey
Adding fuel to the debate, a Hone Health survey published this week found that 50% of current peptide users mistakenly believe the compounds they’re taking are FDA-approved. The survey of 2,491 US adults also found that 60% of peptide users are taking at least one research-grade compound - the category that cannot legally be compounded into prescription medications.
The findings highlight a knowledge gap that’s relevant on both sides of the regulatory argument. People are using compounds without fully understanding their regulatory status or the evidence base behind them.
What This Means
The late July advisory committee meeting is shaping up to be a pivotal moment for peptide regulation. If the committee recommends adding peptides to the 503A Bulks List despite the FDA staff’s concerns, it would represent a significant shift in how the agency approaches these compounds. If it follows the staff recommendation, expanded access could be delayed indefinitely.
For the Australian research community, the US regulatory developments matter because they influence global supply chains, research investment, and the broader conversation about how peptides should be regulated. The TGA takes a different approach to scheduling, but FDA decisions ripple outward.
We’ll be watching the late July meeting closely and reporting on the outcomes.
Sources
Source: FDA staff review ahead of advisory committee meeting (MedPage Today, 1 July 2026)
Source: FDA advisory committee for peptides stocked with conflicts of interest (Healio, 1 July 2026)
Source: FDA staff question peptides backed by Kennedy ahead of advisory panel review (Reuters, 1 July 2026)
Source: RFK Jr. wants to make it easier to get peptides. FDA scientists disagree. (NBC News, 30 June 2026)
Source: 50% of peptide users are taking compounds not approved for human use (Hone Health via AOL, 30 June 2026)
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.